RecruitingNCT07798674
Neurological
Hereditary Spastic Paraplegia
Also known as HSP, Strümpell-Lorrain disease, familial spastic paraplegia, SPG subtypes
Hereditary spastic paraplegias (HSPs) are a clinically and genetically heterogeneous group of neurodegenerative disorders unified by progressive lower limb spasticity due to corticospinal tract degeneration. Over 80 genetic subtypes (SPG1-S
ORPHA:685 ↗Gene SPAST (SPG4)Gene ATL1 (SPG3)Gene REEP1 (SPG31)Gene SPG11Gene CYP7B1Prevalence 1-9 per 100,000 (Orphanet)Onset Childhood, AdultAutosomal dominant, autosomal recessive, or X-linked genetic
21
studies recruiting now
as of 7 Sept 2026
57
studies registered in total
as of 7 Sept 2026
10
countries with a recruiting site
as of 7 Sept 2026
1 Sept 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingNCT06092346
A Natural History Study Seeks to Understand the Clinical, Genomic, Pharmacological, Laboratory, and Dietary Determinates of Pyrimidine and Purine Metabolism Disorders
RecruitingPhase 1 / Phase 2NCT05518188
Melpida: Recombinant Adeno-associated Virus (Serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt)
RecruitingNot applicableNCT07417943
Neuromodulation to Enhance Motor Function in HSP
RecruitingPhase 3NCT06692712
Phase 3 Efficacy Study With Concurrent Control of IT MELPIDA in SPG50.Concurrent Controls.
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 21 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Hereditary Spastic Paraplegia study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
Registry: SPF Patient Registry · Join ↗. Registries connect patients to researchers and often hear about trials first.
About Hereditary Spastic Paraplegia
Hereditary spastic paraplegias (HSPs) are a clinically and genetically heterogeneous group of neurodegenerative disorders unified by progressive lower limb spasticity due to corticospinal tract degeneration. Over 80 genetic subtypes (SPG1-SPG86+) have been identified. Pure HSP involves spasticity and mild proprioceptive sensory loss; complicated HSP includes additional features such as intellectual disability, cerebellar ataxia, peripheral neuropathy, or thin corpus callosum. SPG4 (SPAST) is the most common, accounting for ~40% of autosomal dominant HSP.
Common clinical features
Progressive lower limb spasticityGait difficulty and scissor gaitUrinary urgency and incontinenceMild lower limb weaknessDistal muscle wasting (complicated forms)Cerebellar signs (complicated forms)Peripheral neuropathy (complicated forms)
From Orphanet’s phenotype annotations (CC BY 4.0). Not a complete list.
Treatments being studied
2 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Phase 2Miglustat (Miglustat dipharma)
Phase 1 (early)Leucovorin Calcium (Leucovorin calcium)
Before you apply
Things trial teams commonly ask about for Hereditary Spastic Paraplegia. Not eligibility rules; those are set by each study.
- HSP subtype must be genetically confirmed — SPG4 (SPAST) trials differ from SPG11 or CYP7B1 trials
- Spastic Paraplegia Rating Scale (SPRS) is the primary outcome measure — baseline score should be documented
- Spasticity assessments (Modified Ashworth Scale) and gait analysis are standard baseline eligibility measures
- Complicated HSP subtypes (SPG11, SPG15) may qualify for leukodystrophy or thin corpus callosum trials as well
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).